Reducing Supply Risk in Infectious Disease & Vaccine Trials

Supply risk in infectious disease and vaccine research is usually framed as a question of running out. The harder problem is distributing product precisely.

Trials can enroll thousands of participants in weeks, with sites activating close together and cold chain held continuously from manufacturing to administration. At that volume, a single unnoticed temperature excursion can compromise product before anyone sees it. Protocol amendments arrive more often than in other therapeutic areas: a new variant, an added age cohort, another comparator arm, sites switched on in a surge. Supply models built for steady, staged enrollment strain under that pace.

See how randomization and trial supply management can be set up for a study designed to move in days.